Skip to Content

XTL Biopharmaceuticals Ltd ADR XTLB

Morningstar Rating
$0.86 +0.01 (1.69%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

XTLB is trading at a 55% discount.
Price
$0.87
Fair Value
$3.33
Uncertainty
Extreme
1-Star Price
$75.38
5-Star Price
$4.21
Economic Moat
Jzgv
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if XTLB is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.85
Day Range
$0.770.86
52-Week Range
$0.751.54
Bid/Ask
$0.33 / $0.94
Market Cap
$4.68 Mil
Volume/Avg
11 / 2,569

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren’s syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
4

Valuation

Metric
XTLB
Price/Earnings (Normalized)
Price/Book Value
1.93
Price/Sales
Price/Cash Flow
Price/Earnings
XTLB

Financial Strength

Metric
XTLB
Quick Ratio
13.62
Current Ratio
14.09
Interest Coverage
−131.12
Quick Ratio
XTLB

Profitability

Metric
XTLB
Return on Assets (Normalized)
−23.23%
Return on Equity (Normalized)
−24.47%
Return on Invested Capital (Normalized)
−23.97%
Return on Assets
XTLB
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRVtnq$546.8 Bil
VRTX
Vertex Pharmaceuticals IncGhwsgcb$112.0 Bil
REGN
Regeneron Pharmaceuticals IncRbhbf$108.6 Bil
MRNA
Moderna IncJqqq$35.9 Bil
ARGX
argenx SE ADRKry$24.1 Bil
BNTX
BioNTech SE ADRKcnp$22.2 Bil
ALNY
Alnylam Pharmaceuticals IncFpywww$20.0 Bil
BMRN
Biomarin Pharmaceutical IncPrbfgcs$17.0 Bil
RPRX
Royalty Pharma PLC Class ADbcxwl$14.0 Bil
INCY
Incyte CorpRmsyklf$13.6 Bil

Sponsor Center